🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525342-29-00
Authorised Phase I

A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 mg Tablet in Healthy Adults Under Fed Conditions

2026-525342-29-00 · tracked via the Priya Life Science EU tracker
Sponsor
Pfizer Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Pathological Conditions, Signs and Symptoms
Decision date
11/03/2026
Enrollment target
24
Sites
Belgium

Condition studied

Transthyretin amyloidosis

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525342-29-00 on CTIS ↗ ← All trials in the EU